The biologic license application for cosibelimab for patients with metastatic or locally advanced cutaneous squamous cell carcinoma is supported by findings from a phase 1 study. A biological license application has been submitted to the FDA for cosibelimab (CK-301) anti-PD-L1 antibody under investigation as a treatment for patients with metastatic cutaneous squamous cell carcinoma (cSCC) […]